SP
UTHR icon

SIH Partners’s United Therapeutics UTHR Stock Holding History

SIH Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,875
Closed -$886K – 305
2025
Q1 		$886K Buy
+2,875
New +$985K 0.03% 126

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

SIH Partners's UTHR Position: Q2 2025 in Review

SIH Partners sold out of United Therapeutics (UTHR) in Q2 2025, closing a stake of 2,875 shares — an estimated $886K sold.

SIH Partners first reported a position in UTHR in Q1 2025 and held it in 1 quarter. The position peaked at $886K in Q1 2025. 670 funds tracked by Wall St. Rank hold UTHR as of Q2 2025.

  • SIH Partners reported no remaining United Therapeutics position as of Q2 2025 after selling out during the quarter.
  • SIH Partners sold 2,875 United Therapeutics shares in Q2 2025, an estimated $886K.
  • SIH Partners first reported a position in United Therapeutics in Q1 2025 and held it in 1 quarter.
  • SIH Partners's United Therapeutics position peaked at $886K in Q1 2025.
  • 670 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2025.

Based on SIH Partners's 13F filing for Q2 2025, filed 14 Aug 2025.